I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

PR Newswire
September 10, 2022 — 21:00 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Beijing biotech China chinese Congress Covid-19 European guangdong Guangzhou Hangzhou healthcare Hong Kong investment manufacturing medicine Pandemic Shanghai Signal social media stock market technology Twitter United States University Wechat

Related News:

Keith Payne joins Nintex as Vice President, APAC Sales

December 7, 2023 — 04:07

Supermicro Extends AI and GPU Rack Scale Solutions with Support for AMD Instinct MI300 Series Accelerators

December 7, 2023 — 04:00

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

December 6, 2023 — 08:16

Relais & Châteaux chefs pledge to stop serving eel with immediate effect to prevent its extinction

December 5, 2023 — 16:43

Masdar Expands European presence with Acquisition of 1GW Renewable Portfolio in Poland

December 5, 2023 — 01:34

EarFun Revolutionizes Wireless Audio with Free Pro 3 – The World’s First Snapdragon Sound and Hi-Res ANC Earbuds

December 5, 2023 — 01:00

Ubie’s AI Symptom Checker Used by 2 Million Americans in First Year, Fueling Pharma Partnerships

December 5, 2023 — 00:00

MeltMed® Rings in the Holidays with Reduced Pricing and New NAD+ Starter Packs

December 4, 2023 — 15:01

Media Tour Witnesses Chinese Modernization in Hainan FTP

December 3, 2023 — 16:07